Introduction
In this review, we cover the two broad classes of anchorage dependent stem cells (human mesenchymal and pluripotent stem cells) with the greatest promises for cell therapy success in clinical trials. Both of these cell types are universally grown in 2 dimensional (2D) cultures. However for large scale production, there is a shift towards 3 dimensional (3D) suspension cultures, in particular with the use of microcarriers (MCs) in bioreactors. This article begins with reviews on these two cell types, their growth requirements, use in clinical trials and potential applications. MC technology and their usage in stem cell expansion and differentiation are subsequently depicted. Challenges still to be overcome are also highlighted, as the production of large doses of cells becomes necessary for late stage clinical trials and commercialization.
Multipotent and pluripotent stem cells: source, mode of growth and applications in clinical trials

Sources of multipotent/mesenchymal stem cells
Multipotent or mesenchymal stem cells (MSCs) are attracting increasing interest for possible application in cell therapies. MSCs encompass a broad range of anchorage dependent fibroblast-like cells which can be obtained from bone marrow aspirates, skeletal muscle connective tissue, human trabecular bones, adipose tissue, periosteum, fetal blood and liver, and umbilical cord blood, as reviewed by Oh and Choo (2011) . Homogeneous MSCs can also be derived from human embryonic stem cells (hESCs) (Lian et al., 2007; Olivier et al., 2006) . MSC express the CD29, CD44, CD73, CD90, CD105 and primitive Stro-1 markers (Dominici et al., 2006) . They can proliferate in vitro and differentiate into mesoderm-type lineages, including osteoblasts, chondrocytes, adipocytes, myocytes and vascular cells. Due to this ability, MSC provide a versatile source of progenitor cells for research and clinical applications in the field of tissue regeneration.
Mode of growth
MSCs are typically grown on plastic tissue culture dishes as monolayers with no additional coatings (Fig. 1A and C) . Basal media supplemented with fetal calf serum between 5 and 10% is widely utilized, but its use in the context of clinical applications is associated with several risks such as viral and prion transmission (Bernardo et al., 2007; Govindasamy et al., 2011; Shahdadfar et al., 2005) or immunological reactions (Selvaggi et al., 1997; Tuschong et al., 2002) . Several new serum free media such as MesenCult®-XF Medium (Stemcell Technologies), StemPro® MSC SFM (Life Technologies), MSC Nutristem® XF Medium (Biological Industries), BD Mosaic™ (Becton Dickinson) in conjunction with surface coatings with proprietary extracellular matrices are now becoming available from companies such as Life Technologies, StemCell Technologies, Biological Industries and Becton Dickinson.
Differentiation capabilities
The tri-lineage differentiation capability of MSCs into osteoblasts, adipocytes, and chondrocytes has been evaluated by many groups. Osteogenesis requires MSCs to be incubated with β-glycerol-phosphate, ascorbic acid-2-phosphate, dexamethasone and fetal bovine serum. MSCs should reveal osteoblastic morphology together with high expression of alkaline phosphatase and calcium deposition. To view osteoblast generation, Von Kossa staining is a technique which subjects cell cultures to silver nitrate solution. Calcium is then reduced by light and silver deposits generated, which can be visualized by microscopy (Chase et al., 2010) . For adipogenesis, MSC cultures are incubated with isobutylmethylxanthine to form adipocytes with lipid vacuoles. This process is induced by nuclear receptor, PPAR-γ, transcription factors and fatty acid synthetase. Lipid vacuoles are detected by oil red O staining; a fat soluble-oil for staining lipid and fat in culture sections (Chase et al., 2010) . Chondrogenesis is performed in a 3D culture pellet, with a serum-free nutrient medium and transforming growth factor-β3 (TGF-β3). Under such conditions, MSCs quickly change their fibroblastic appearance and express cartilage-specific matrix-layers filled with glycosaminoglycans. Toluidine blue indicator, a polychromatic dye, is used to stain for glycosaminoglycan-containing components (Chase et al., 2010; Zhang et al., 2011) . In addition, such differentiated MSCs can generate type II collagen, another cartilage component .
Other than these three lineages, MSCs are believed to be able to differentiate into myoblasts, cardiomyocytes and even neurons. Formation of cells of non-mesodermal origin may be a result of a phenomenon known as "stem cell plasticity", a transdifferentiation process in which organ-specific stem cells are no longer restricted to forming the differentiated cell types of the tissue where they reside (Lakshmipathy and Verfaillie, 2005) .
Clinical trials and applications
A recent review of clinical trials for stem cell therapies describes the use of MSC in addressing diseases ranging from cancer, diabetes, bone, cartilage, heart, gastrointestinal, immune and neurodegenerative diseases (Trounson et al., 2011) . Below, we highlight a few late stage trials where significant cell doses are needed for these therapies.
2.4.1. Immuno-modulatory therapy 2.4.1.1. Acute graft-versus-host disease. MSCs have shown promising clinical potential for immuno-modulatory therapy. Osiris Therapeutics' product, Prochymal, which are MSCs expanded from healthy adults' bone marrow has been evaluated in phase III clinical trials for both steroid refractory and acute graft-versus-host disease (GVHD). In a successful phase II clinical trial, human MSCs were used to treat de novo acute GVHD. Patients suffering from grades II-IV GVHD were randomized for two Prochymal dosages of 2 or 8 million MSCs per kg, together with infusion of corticosteroids. Prochymal achieved 94% in overall response rate with an outstanding complete remission rate of 77% from the 32 patients. Most of these GVHD symptoms disappeared by day 18 after MSC injection. In addition there was neither administrative harm nor ectopic tissue development. Regardless of the dosage levels, safety and efficacy levels remained the same, showing the remarkable ability of MSCs for the treatment of acute GVHD (Kebriaei et al., 2009) . Prochymal has now received approval for clinical use in pediatric patients in Canada. Since then there have been other studies published of MSCs for the treatment of acute GVHD (Herrmann et al., 2012; Kuzmina et al., 2012) .
2.4.1.2. Crohn's disease. Prochymal is also applied in clinical trials for the treatment of moderate to severe Crohn's disease. In a phase I trial, autologous derived MSCs reduced the Crohn's disease activity index in 9 patients with 2 doses of cell infusion (Duijvestein et al., 2010) . In phase II studies, patients' inflamed intestines showed diminishing inflammatory conditions and crypt regeneration following Prochymal treatment. In an open label trial, 10 patients with Crohn's disease were randomly selected, who had failed to show improvement by treatment with steroids, Methotrexate, and Remicade previously. By day 9 of Prochymal injection, there were signs of recovery such as intestinal inflammation and ulceration reduction as well as crypt formation in some patients. By day 28, every patient saw a drastic drop in Crohn's disease severity and at the same time, tolerated Prochymal relatively well, suggesting that MSCs may be suitable to treat Crohn's disease. Unfortunately, the phase III trial of Prochymal for Crohn's disease halted patients' enrolment because of a design flaw which resulted in significantly higher than expected placebo response rates (Allison, 2009 ). Osiris has since had an extended evaluation of the trial and has successfully completed the study but has not yet published.
Bone regeneration
Osteogenesis Imperfecta (OI), a bone disease can be treated with MSC transplantation. Due to the production of abnormal type I collagen in bones, slow bone development, frequent fractures, and bone distortion occurs. Horwitz et al. (1999) transplanted bone marrow cells from HLA-identical siblings to OI patients and showed about 2% of the osteoblasts in recipient's bone marrow came from the donor. These MSC can develop into normal osteoblasts, leading to fast bone development and reduced fracture frequencies (Horwitz et al., 1999) .
Subsequent trials done with children resulted in significant gain in total body length with a median of 7.5 cm, six months post transplantation. Bone mineral content improved by 45-77% of baseline values and frequency of fractures dropped from 10 to 2. Follow-up investigations showed that the introduction of purified allogenic bone marrow MSCs gave even better therapeutic results for the treatment of OI (Horwitz et al., 2002) .
A more recent clinical trial makes use of in utero MSC transplantation in patients with severe OI. Findings showed that allogenic fetal MSC can engraft and differentiate into bone in the human fetus even when the recipient is immuno-competent and HLA-incompatible (Le Blanc et al., 2005) . The Children's Hospital of Philadelphia in the USA is currently recruiting study subjects for their phase I study to assess the safety and feasibility of repeated infusions of MSC in children with OI (ClinicalTrials.gov Identifier: NCT01061099). MSC therefore appears particularly promising for bone regeneration.
Cartilage regeneration
The application of autologous bone marrow derived MSCs into patients with Osteoarthritis has been reported. Twelve patients received MSC injections into articular cartilage defects located in their knee joints and results were compared with a control group without MSC treatment. MSC transplantation resulted in defects being covered with white soft tissue that displayed more desirable arthroscopic and histological grading properties than the controls (Wakitani et al., 2002) . This study demonstrated the possibility of using MSCs for cartilage repair. A clinical study of articular cartilage regeneration is being investigated using umbilical cord blood-derived MSCs to treat older patients who possess large defects which do not heal easily. This study was conducted by MediPost which has recently completed a phase III clinical trial comparing the efficiency and safety between their product, CARTISTEM® (allogeneic-unrelated umbilical cord blood derived MSCs), and microfracture treatment (controls) in patients with knee articular cartilage defects. This product was recently approved by Korean Food and Drug Administration for clinical use.
Myocardium regeneration
In a recent human study, patients were chosen at random for the intracoronary introduction of autologous bone marrow MSC following myocardial infarction (MI). After three months, it was observed that the heart's damaged region has reduced by a greater amount, coupled with more significant improvements in contractility and heart function versus patients who underwent standard therapy. Although the exact mechanism behind myocardium regeneration remains unknown, the study shows the promise of MSCs for tissue engineering and regeneration applications (Strauer et al., 2002) .
Presently, Osiris Therapeutics is starting phase II clinical trials for the treatment of acute MI using Prochymal. Concurrently, they are also conducting a phase I randomized; double-blind, placebo-controlled, dose escalation, and multi-center study to determine the safety of infusing ex-vivo cultured adult MSCs (Provacel) following acute MI (Allison, 2009 ).
Metachromatic leukodystrophy (MLD) & Hurler syndrome
Metachromatic leukodystrophy (MLD) or Hurler's syndrome is a disease that results in severe skeletal and neurological disorders. A clinical trial of patients with MLD, who previously underwent successful bone marrow transplantation from an HLA-identical sibling, has been reported. MSC from a bone marrow aspirate of the original donor was infused into these patients. Of the six patients with MLD, four showed significant improvements in nerve conduction velocities after MSC transplantation (Koç et al., 2002) . Furthermore, the bone mineral density either improved or remained unchanged in all patients. More importantly, there were no apparent adverse effects in all patients after MSC infusion. Thus allogenic MSC infusion may be a suitable treatment of patients with MLD.
Based on the review of a selected range of disease types and injuries, it appears that tens of millions to billions of MSC will be required per patient per transplantation (Table 1) .
Pluripotent stem cells, hESCs and hiPSCs
The first human embryonic stem cells (hESCs) were derived by James Thomson and his co-workers in 1998, using frozen or fresh blastocysts left over from infertility treatment of couples that had undergone in vitro fertilization (IVF). The blastocysts were cultured from the initial cleavage stage embryos and 14 inner cell masses (ICM) were isolated from the blastocysts. From these, five cell lines were derived (Thomson et al., 1998) . Besides Thomson's method, hESC can also be derived from non-viable embryos that are produced by IVF that have undergone irreversible cessation of cell division and are no longer suitable for the purpose of reproduction. However, these embryos still retain some normal blastomeres suitable for the derivation of stem cells.
In 2007, Takahashi and Yamanaka discovered a new method of generating human induced pluripotent stem cells (hiPSCs) which have pluripotency properties similar to hESCs, by transfecting 4 genes to human fibroblasts (Takahashi et al., 2007) . This opened the floodgates of new approaches for creating hiPSCs using Retroviruses, Lentiviruses, Sendai virus, mini-circle plasmids, mRNA, microRNA and recombinant proteins (Robinton and Daley, 2012) . hiPSC express pluripotency markers such as Oct4, Nanog, Sox2, and surface antigens SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81. Many cell types have now been reprogrammed to hiPSC such as fibroblasts, MSC, fat and blood cells thereby enabling the modeling of a range of hematological, neurological, metabolic, cardiovascular, and immunodeficiency diseases (Robinton and Daley, 2012) .
Mode of growth
Initially, hESCs were derived on mouse feeder layers (Thomson et al., 1998) . Subsequently, a variety of stromal layers derived from human feeders and different cell sources were found to be able to support long term hESC culture (Choo et al., 2006) . In the next phase, researchers began to look for fully defined media devoid of the use of feeders. A defined media where every component and additive are known are important if hESCs are to be used in a therapeutic context. It is particularly desirable to eliminate animal derived products due to the potential for transmission of pathogens to the cells. The International Stem Cell Initiative (TISCI) Consortium conducted a comprehensive comparison of 9 different defined culture systems for feeder free propagation of hESCs in 4 separate laboratories and found that most of the formulations did not support maintenance of hESCs for even a relatively short period of the study (Consortium et al., 2010) . The two commercial media (mTeSR®1 hESC SFM and StemPRO® hESC SFM), are the most robust in terms of long term support of hESCs. This may be attributed to the subtleties in media preparation.
The non-defined extracellular matrix (ECM) extract, Matrigel, has been used traditionally as a surface matrix for hESC culture. A study combined four extracellular matrix proteins: collagen IV, fibronectin, laminin and vitronectin, to replace Matrigel for the long-term expansion of hESCs in defined mTeSR®1 hESC SFM (Ludwig et al., 2006) . Others have tried defined ECMs such as human fibronectin (Amit and Itskovitz-Eldor, 2006) , human recombinant laminins 111, 332 (Miyazaki et al., 2008) , and 511 (Rodin et al., 2010) and vitronectin (Braam et al., 2008; Yap et al., 2010) . Recently, Melkoumian et al. (2010) described a synthetic surface, consisting of peptide sequences conjugated to an acrylate polymer, which sustains the propagation of hESCs over 20 passages in defined medium. hESCs were also able to form cardiomyocytes on the peptide surfaces. Using an approach that does not require a hydrogel, Kolhar et al. (2010) report that cyclic-RGD peptide sequences conjugated to tissue culture polystyrene were suitable for propagating hESCs in a defined medium. Both studies verified hESC quality by performing karyotype analysis and pluripotency assays.
Differentiation capabilities
The versatility of both hESCs and hiPSCs to become multiple cell types in the body makes them interesting candidates for studies of developmental biology. It is expected that these cells may eventually find applications in cell therapy. Typically, in vitro differentiation of hESCs into the three germ layers requires the initial formation of embryoid bodies (EBs), which are cell aggregates in suspension. EBs are able to differentiate into several cell lineages such as primitive endoderm, definitive endoderm, mesoderm, ectoderm, and trophectoderm (Doetschman et al., 1985; Itskovitz-Eldor et al., 2000; Takahashi et al., 2007; Yu et al., 2007) . Until now, neurons, glia, endothelial cells, cardiomyocytes, keratinocytes, hepatocyte-like cells, hematopoietic precursors, osteogenic cells, insulin-producing cells, prostate tissue, adipocytes and melanocytes have been differentiated from hESC (Gepstein, 2002; Keller, 2005; Odorico et al., 2001; Pera and Trounson, 2004 ).
An example of an ectoderm lineage is neural differentiation. In the presence of fibroblast growth factor 2 (FGF-2), neural tube-like structures can be formed from EBs. The neural precursors were then isolated from these EBs. With FGF-2 withdrawal, these precursors can be further differentiated into neurons, astrocytes and oligodendrocytes. Transplantation of precursors into the brain of a neonatal mouse, showed that they were incorporated into different parts of the brain, where they formed both astrocytes and neurons (Zhang et al., 2001 ).
An example of a mesoderm lineage is cardiomyocyte differentiation. EBs plated on culture dishes coated with gelatin continued to differentiate for 22 days after plating, with 8% of the EBs containing areas which were contracting rhythmically. Cardiac specific transcription factors and genes were expressed by the cells isolated from these areas. In addition, the cells displayed a functional phenotype of fetal human cardiomyocytes (Kehat and Gepstein, 2001) .
hESCs have been differentiated to 80% definitive endoderm cells in low serum and Activin A. More mature cells of the endodermal organs are produced from these definitive endoderm cells after transplantation under the kidney capsule (D'Amour et al., 2005) . The endodermal cell aggregates expressed various marker genes, such as HNF6, FOXA2 and PDX1 which indicated that they were of the pancreatic endoderm (Kroon et al., 2008) .
Potential applications and clinical trials
At present, there are only a handful of on-going therapies in humans involving hESC (Table 1) compared to MSC where there are 123 (Trounson et al., 2011) . The limited number of hESC related cell therapy trials is partly due to concerns about the tumorigenicity of these cells.
Spinal cord injury
The first human trial of hESC for the treatment of spinal cord injury was approved by the Food and Drug Administration (FDA). Eight to ten patients with severe spinal cord injuries were recruited in a phase 1 trial by Geron, to test the safety of the oligodendrocyte progenitor cells (OPC). In this treatment, a cocktail of growth factors is used to induce hESCs into OPCs before they are injected into the injured spinal cord. Oligodendrocytes play a part in supporting neural cells to restore nerve conduction. Earlier preclinical trials done in adult rats showed that the transplanted hESC-derived OPC enhanced remyelination and promoted the improvement of motor function. The aim of the phase 1 clinical trial was to enhance the repair of the myelin insulation around the nerve cells and thereby re-establish the spinal cord's ability to transmit signals (Keirstead et al., 2005) . Unfortunately in early 2012, Geron made a business decision to stop pursuing this clinical trial.
Retinal pigment epithelial (RPE) transplantation
RPE cells are a derivative of the neuroectoderm which are crucial for the survival of photoreceptors. In age-related macular degeneration (AMD), RPE cells degenerate and cannot be replaced. Studies using animal models have shown that degenerated RPE cells can be replaced by transplanting donor RPE cells, rescuing the host photoreceptors and thereby restoring visual function. hESC has recently been shown to be an excellent source for generating RPE cells (da Cruz et al., 2007) . These hESC-derived RPE cells have shown similar gene expression profiles resembling primary human RPE. Three previous studies have made use of different protocols on mouse embryonic stem cells (mESC) and hESC to form RPE cells prior to transplantation and have found no evidence of any tumor formation, thus showing the clinical promise of hESC-derived RPE cells in treating AMD (da Cruz et al., 2007) .
Recently, the FDA has approved the testing of hESCs for the treatment of Stargardt's Macular Dystrophy (SMD) by Advanced Cell Technology Inc. (ACT). This rare disease destroys the retinal cells of approximately 30,000 people worldwide. Currently, ACT has completed animal studies and is conducting a phase I trial to establish the safety and tolerability of the RPE cells after transplantation into the sub-retina of SMD patients in the US and UK. Preclinical trials in rat models showed a visual performance improvement of 100% without any undesirable effects in the treated rats when compared with their untreated cohorts (Lu et al., 2009 ).
Models of disease and drug screening
As hiPSC can be generated from patient samples of a variety of diseases, they can potentially be used in many disease models (Colman and Dreesen, 2009 ). For example, hiPSCs could be useful models for studying the development of patients with sporadic or familial diseases, including Parkinson's disease, Alzheimer's disease, juvenileonset, type I diabetes mellitus, and Duchenne type muscular dystrophy (Jang et al., 2012) . They could also be used for drug screening for cardiotoxicity to reduce the attrition rate of drugs in development (Zeevi-Levin et al., 2012) . In the future, there will also be a need to generate hepatocytes of adult phenotype for studies of drug metabolism. However, as a cell source for therapy it is still too early to tell, due to their genetic and epigenetic abnormalities after reprogramming.
Microcarrier (MC) technology
The above section shows that large amount of cells are needed for clinical therapies. Since clinical application of these cells will require 10 6 to 10 9 cells per treatment (Table 1) , production of thousands of treatment doses in conventional 2D culture can be challenging. We estimate that cell doses of up to 50 million cells can be produced in one 40 stack Nunc tray handled by robotic or manual manipulation. However, when the demand increases this becomes extremely labor intensive, costly, and impractical (Davie et al., 2012; Rowley et al., 2012) . One of the options for overcoming this obstacle would be a MC based culturing technology. In the following sections, we will describe the availability of MCs for anchorage dependent cells, their properties and advantages compared to 2D culture. Thereafter, we will describe the recent studies showing adaptation of commercial MCs to expand and differentiate MSCs and hPSCs.
Culturing of anchorage dependent cells on MC
Traditionally anchorage dependent stem cells are propagated in 2D tissue culture surfaces. The restricted surface to volume ratio offered by this classical technique creates a bottle neck in the production of cells. In an attempt to provide systems that offer large accessible surfaces for cell growth in a small volume, a number of techniques have been proposed: stacked plates (Wolfe et al., 2008) , hollow fibers and packed bed reactors (Brandenberger et al., 2011) . Since these systems are non-homogeneous in their nature, they suffer from several shortcomings: limited potential for scale up, difficulties in taking cell samples, limited potential for measuring and controlling the system and difficulties in maintaining homogeneous environmental conditions throughout the culture. In order to overcome these limitations, van Wezel (1967) developed the concept of the MC culturing system. In this system, cells are propagated on the surface of small solid particles suspended in the growth medium by slow agitation. The cells would attach and grow to confluence on the surface of the MCs.
Advantages of the MC culturing systems
The MC system is a unit operation in which both monolayer and suspension cultures are brought together. The MC surface is available for cell growth while the mobility of MCs in the medium generates a homogeneity that is similar to the suspension environment used in traditional mammalian and microbial submerged cultures. The major advantages of the MC system are listed below.
1. High surface to volume ratio which can be increased easily by changing the MC concentration. A culture of 3 mg/ml Cytodex 1 MC culture can supply a surface area of 1.32 × 10 4 cm 2 in 1 l which is equivalent to 176 tissue culture flasks with 75 cm 2 each.
This single unit operation leads to reduction in laboratory space, and the number of handling steps per cell, thus reducing labor costs and risks of contamination. 2. A homogeneously stirred MC suspension culture allows monitoring and controlling of various environmental parameters (e.g. pH, pO 2 , concentration of medium components), leading to more reproducible cell culture. A representative cell sample can be taken for microscopic observation and cell characterization. 3. MC cultures can be scaled up with ease in conventional stainless steel or disposable bioreactors that are used for propagation of suspended mammalian cells.
4. Macroporous MCs can protect cells from shear stress created by the stirrer, sparger or spin filter in the bioreactor (Blüml, 2007; Ng et al., 1996) . 5. MCs can enable scale up by cell to cell transfer without the use of proteolytic enzymes (Blüml, 2007; Wang and Ouyang, 1999) . 6. Perfusion cultures are easier to operate with MC culture since medium can be easily harvested on line by filtration or decantation (Blüml, 2007; Butler et al., 1983; Serra et al., 2010) . 7. MCs can be used for propagation of cells in 3D culture and for studying co-cultures and cell-cell interactions (Martin et al., 2011) . 8. Biodegradable MCs can be used as the scaffold for in vivo transplantation of cells (Chung et al., 2008; Martin et al., 2011; Thomson et al., 2010) .
These unique properties illustrate the reasons for the extensive use of MC cultures in viral vaccine production (Tree et al., 2001 ) and other laboratory scale applications.
General requirements and properties of MCs
MCs were initially developed for supporting the growth of anchorage dependent mammalian cells (primary cells, diploid cell strains and transformed cell lines). Various types of MCs were developed (Table 2) . Different MC properties can affect cell attachment, spreading, growth and differentiation. The general requirements and physical properties are discussed below.
Functional attachment and growth supporting elements on the MC surfaces are critical. The surface of a MC can be derivatized with functional groups such as positively charged tertiary quaternary or primary amines, gelatin, collagen, other extracellular matrix (ECM) proteins and peptides (e.g. RGD peptide). The positively charged MCs attract the cells (which are negatively charged), by electrostatic forces. The optimal amount of positive charge was found to be between 1 and 2 milliequivalents/g dry materials (for cross-linked dextran or polyacrylamide beads derivatized with tertiary amines) (Himes and Hu, 1987; Reuveny et al., 1981 Reuveny et al., , 1983 . At this level, cells attach to the MCs efficiently (about 90% within 1 h) without negative effect on cell growth. Coating with collagen or ECM protein results in lower cell attachment but usually supports better growth of cells at low inocula levels.
MCs can be produced in various shapes and sizes, spherical being the most common. Each MC should have the dimensions that can facilitate cell growth for several doublings. In this way at the end of the cell growth, each MC will support several hundred cells on its surface. For spherical MCs, diameters of 100-230 μm are reported to be the preferred size (Markvicheva and Grandfils, 2004) . The size distribution of the spherical MC should be low (± 25 μm) in order to prevent uneven distribution of cells on the MCs. Density of the MC should be slightly above 1 (1.02-1.05 g/ml) in order to maintain the MCs in suspension at minimal agitation speed. Furthermore, the agitation type and speed and oxygen delivery method need to be optimized to prevent cell detachment and to minimize shear forces on the cells. The matrix of the MC should be rigid enough in order to support cell spreading and withstand any mechanical forces encountered during the cell cultivation. Lastly, the MCs are preferred to be transparent for direct observation of cells and heat tolerant for steam sterilization.
Commercial MCs
A wide variety of MCs are available commercially ( (Reuveny et al., 1981 (Reuveny et al., , 1982 . Group 2 Collagen coated MCs (e.g. Cytodex 3 and FACT 102-L). These
MCs are chemically coupled with collagen and are suitable for culturing sensitive cells with low plating efficiency. The collagen coating is also designed to facilitate cell harvesting. Group 3 ECM coated MCs (Pro-F 102-L). Pro-F 102-L is coated with recombinant fibronectin which is designed for culturing of sensitive cells in serum free conditions. Group 4 Non-charged MCs (e.g. Glass beads and tissue culture Polystyrene MC P 102-L). These MCs have similar surface properties as classical 2D tissue culture surfaces. Group 5 Macroporous MCs (e.g. Cytopore and Cultispher). Macroporous
MCs with pore sizes in the range of 10-70 μm on the surface. They provide higher cell surface areas for growth and offer better mechanical protection to the cells from shear stress generated by stirrers, spargers or spin filters. Group 6 Weighted MCs (Cytoline). These MCs are designed for use in fluidized bed perfusion cultures.
These commercial MCs have been designed according to the needs for propagating anchorage dependent cell lines used in production of vaccine and biopharmaceuticals. The following section will provide insight into the adaptation of these MCs for MSC and hPSC expansion and differentiation.
Propagation and differentiation of MSC on MCs
MSCs grow as a monolayer on tissue culture treated polystyrene surfaces in serum containing or serum free media exhibiting fibroblast-like morphology (Fig. 1A) . Cells are seeded at densities of 1-3 × 10 3 cells/ cm 2 and at confluence, average cell densities of 2.5 × 10 4 cells/cm 2 can be achieved (Rowley et al., 2012) . As shown in Table 1 , MSC dosage used in clinical applications can be as high as 6 billion cells for treating Osteogenesis Imperfecta. Such large cell numbers would make the current 2D cell culture platform technically and economically untenable. It is therefore, imperative to consider microcarriers as the alternative platform (Rowley et al., 2012) .
Selection of MCs for MSC expansion
Several types of MCs having different surface chemistry, matrix, size, and porosity have been tested for MSC propagation (Table 3 ). The choice of the optimal MC depends mainly on the cell type and final use of the cells. Timmins et al. (2012) compared different MCs for supporting proliferation of human placental derived MSCs. Seeding efficiency was over 70% for several MCs (Cytodex 1, 3 and Cultispher S). Cultispher S yielded the highest cell attachment rate (over 90% efficiency) and a 15-fold cell expansion. Schop et al. (2010) tested a similar set of MCs for the expansion of human bone marrow derived MSCs. Cytodex 1 generated the highest seeding efficiency and growth, achieving 4.8 fold expansion and final cell density of about 6 × 10 5 /ml. Yang et al. (2007) tested Cytodex 1, Cytopore 2 and Cultispher S for supporting rat bone marrow derived MSCs and again found Cultispher S gave the best results. Goh et al. (2013) compared Cytodex (1 and 3) and Cultispher MCs for supporting fetal human MSC and found that Cytodex 1 and 3 resulted in the highest cell yields (8 × 10 5 cells/ml). The study chose Cytodex 3 instead of Cytodex 1 because it resulted in lower aggregate formation rates and the collagen coating facilitated efficient cell harvesting at the end of the culture. In summary, in several studies where different MCs were screened, Cultispher S, Cytodex 1 and 3 MCs were usually selected for the expansion of MSCs. The choice of MC depends on the particular cell line, cell growth morphology, and harvesting efficiency. Zhou et al. (2011) used experimentally produced biodegradable MCs like gelatin beads and fabricated micronized dermal matrix and small intestinal sub mucosa for direct implantation into mice. The main concern when using these types of MCs is the issue of safety like biocompatibility of the MC matrix in the body. Zhou et al. (2011) reported good compatibility of the experimentally produced MCs. Further work is needed in order to generate current Good Manufacturing Practices (cGMP) compliant biodegradable MCs and to prove their biocompatibility.
Culturing of MSC on MCs
For preliminary screening of culture conditions, MC cultures are carried out in lab scale devices like petri dishes and tubes, which can operate either in static or agitated conditions (Timmins et al., 2012; Yang et al., 2007) . However, demonstration of scalability is limited as most of the studies were performed in 100-250 ml spinner flasks (Fig. 1C) , without regulation of oxygen and pH (Table 3) . In these cultures, MSCs are seeded at a concentration of 3-5 cells per bead achieving 7-20 fold expansion. Under optimal conditions, cell confluency on MC is about 50 cells per Cytodex 3 bead and a surface density of 2-4 × 10 4 cells/cm 2 can be achieved (Fig. 1B) . Volumetric cell yields between 2 and 10 × 10 5 cells/ml have been reported, depending on the cell type and the culture conditions (Table 3) . Most of the works cited in the preceding paragraph were conducted in fetal calf serum containing media. For cGMP production, xeno-free defined media would be preferred. Santos et al. (2011a) used polystyrene based MCs coated with xeno-free proprietary cell adhesive substrate (CELLstart™, Life Technologies) in order to propagate adipose and bone marrow derived MSCs in a serum free spinner flask culture, achieving cell densities of 1.4 × 10 5 and 2 × 10 5 cells/ml respectively (cell fold expansions of 14 and 18 respectively). Usually an extensive medium replenishment regime, every 2-3 days, is required to achieve high cell densities. This feeding regime is excessive, costly and unsuitable for large scale production. Limited work has been undertaken to optimize the feeding regimes (Eibes et al., 2010; Sart et al., 2010; Schop et al., 2010; Sun et al., 2010) . Thus, a reasonably priced xeno-free medium with optimally designed feeding regime will serve to enable the large scale production of MSCs. In addition, more detailed studies on MSC metabolism, requirements for essential growth factors and the development of efficient nutrient and growth factor feeding strategies will be important to reduce production costs.
Scaling up MC culture for MSC expansion
The scale-up of MSC MC cultures in large bioreactors has not been reported in the literature. Preliminary data on potential scale-up in the Wave reactor has been reported by Timmins et al. (2012) . Recently, Goh et al. (2013) used a pH and dissolved oxygen controlled 1 l bioreactor to demonstrate the scalability of a human fetal MSC culture; a yield of 8 × 10 5 cells/ml was obtained. Several groups (Frauenschuh et al., 2007; Sart et al., 2010; Schop et al., 2010) have provided preliminary spinner culture data describing the potential use of bead-to-bead cell transfer for culture scale up. The effect of spinner impeller geometry on cell expansion was investigated by Hewitt et al. (2011) . These studies pave the way for more work in developing a scalable production system in controlled reactors (Fig. 1D) .
Cell harvesting
One of the main obstacles of using MC culture for propagating MSCs is efficient cell harvesting from the MC surface and separation of the MCs from the harvested cells. This issue has received little attention until now. Recently, Goh et al. (2013) have compared the use of trypsin, recombinant cell dissociation enzyme TryPLE Express (Life Technologies) and Collagenase I for harvesting MSC expanded on Cytodex 3 MCs. Trypsin was found to be the most suitable enzyme with highest cell detachment rate of more than 80% in 5 min without significantly affecting the harvested cell viability. MSCs harvested from Cytodex 3 were further characterized and compared to those harvested from tissue culture flasks. No significant differences were found between MSC harvested from these two culturing platform in terms of their immuno-phenotype, self-renewal capacity and proliferation potential (Goh et al., 2013) . Currently, investigations on the scalability and the integration of cell harvesting with the bioreactor platform are in progress.
Differentiation
In most of the above studies the potential of the MC propagated MSCs to differentiate to the three mesoderm lineages is demonstrated, mainly by histological data without performing a quantitative assessment of differentiation efficiency to a specific lineage and testing in vivo functions. There are a few preliminary reports demonstrating directed differentiation of MSC from MC cultures to a specific lineage. Zhou et al. (2011) expanded human adipose derived MSCs in MC culture and described their in vivo use in soft tissue skin regeneration in a nude mouse model. Tseng et al. (2012) later reported spontaneous osteogenesis of MSCs due to alteration of cytoskeletal tension in 3D MC cultures. Chen et al. (2011b) used aggregated cell-MC structures to generate large cm size bone structures in a perfusion chamber. Yang et al. (2007) described in vivo transplantations of bone marrow derived rat MSCs on MCs into rat bone defects and examined in vivo osteogenesis. Recently Goh et al. (2013) have quantified the in vivo and in vitro osteogenesis efficiencies of fetal human MSCs propagated in MC cultures. Results show that cells propagated on MCs exhibit higher levels of calcium deposit when differentiated on polycaprolactone scaffold or transplanted into mice, as compared with MSCs harvested from 2D culture.
Propagation and differentiation of human pluripotent stem cells on MCs
Classical expansion of human pluripotent stem cells (hPSC), which includes human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC), are usually carried out in 2D tissue culture plates ( Fig. 2A) . This 2D culturing platform may be sufficient for early clinical trials or cell therapy that requires a small number of cells, such as retinal pigment epithelial cells for treatment of macular diseases. However, there is a need for a scalable expansion platform to produce differentiated cells like cardiomyocytes and hepatocytes from hPSC to meet future cell therapies, requiring millions of cells per adult patient or for drug testing applications.
Expansion and differentiation of hPSC using MCs with various coatings have been demonstrated and proven to be feasible for large scale production (Table 4) . It is important to consider the choice of MCs and the bioreactor operating conditions that not only affect the cell growth but also impact pluripotency and lineage commitments. This review will discuss critical factors affecting the culture of hPSC on MCs and related bioreactor conditions.
Mouse embryonic stem cells, having been extensively studied in the past, are not included in this review, due to their limited relevance to clinical applications.
Several groups have developed cultures of MC-free cell aggregates with advantages of reducing cost and simplifying cell harvesting. These protocols have demonstrated scalability and achieved up to 1.89 × 106 cells/ml (17.7 fold expansion) (Amit et al., 2011) while maintaining pluripotency and normal karyotype. The key to effectively establish the aggregate cultures is the formation of homogeneous aggregates with consistent size. This has been reported to be a challenging hurdle due to significant loss of initial cell viabilities (28-76%) during aggregate formation (Olmer et al., 2010; Singh et al., 2010) . To overcome this, addition or increasing the concentration of growth factors or inhibitors (Amit et al., 2011; Kehoe et al., 2010; Krawetz et al., 2010; Larijani et al., 2011; Olmer et al., 2010; Singh et al., 2010) , and transient heat shock treatment (Singh et al., 2010) has been used to improve cell viability. During the cultivation of the aggregate culture, it is important to limit cell aggregate size as cells will have difficulty accessing nutrients and growth factors to maintain self-renewal of hPSCs (Amit et al., 2011; Chen et al., 2012) . Disaggregation is performed usually through manual manipulation, which might undermine the scalability of the platform. An updated review regarding aggregate cultures of hPSCs can be found in O'Brien and Laslett (2012). Hence, aggregate culture will not be discussed further in detail due to the scope of the review.
Selection of MCs for hPSC expansion
The selection of suitable MCs is the first step to establish a MC based platform. Different hPSC cell lines were propagated on variety of MCs. Several groups have screened MCs for the cultivation of hPSC by examining initial cell attachment followed by monitoring cell growth over a prolonged length of time (Chen et al., 2011a; Lock and Tzanakakis, 2009; Nie et al., 2009; Phillips et al., 2008) . The reported data indicate that the commercial MCs are not suitable for hPSC cultivation without any surface modification. It seems that similar to the 2D hPSC culturing platform, Matrigel coating on MCs had a profound effect on improving cell growth and pluripotency in long term cultures. Chen et al. (2011a) shows that cell yields were higher in Matrigel coated MCs by 1.9 to 18 fold compared to the uncoated ones. Cells cultivated on Matrigel coated carriers exhibited high viability (over 90%) with no necrosis or cell death. These cells can be cultured for many passages by transferring them directly into new MCs or plating them on 2D plates. They have also screened different ECM components for hESC growth and identified laminin as a suitable replacement for Matrigel coating on MCs. Similar cell growth and pluripotent marker expressions levels were observed using Matrigel or laminin coated MCs. Later a study by Heng et al. (2012) took the MC platform further by propagating hESCs on laminin and vitronectin coated MCs in serum free medium. Both laminin and vitronectin coated MCs performed equally well in long term culture with respect to cell growth, pluripotent marker expressions, in vitro and in vivo pluripotency and karyotype. In the attempt to eliminate the need for ECM coating, our group has identified that by addition of ROCK inhibitor (Y27632) to the culture medium, hPSCs can attach and grow on uncoated MCs obtaining similar cell yields as ECM coated ones while still upholding pluripotency and karyotype stability (Chen et al., submitted for publication) .
There is no consensus regarding which would be the most suitable MCs for hPSC expansion. A study by Chen et al. (2011a) has explored the effect of size, shape, porosity, coating and surface charge of MCs on hESC growth using ten readily available commercial MCs and chromatographic materials. It was found that MC size and shape affected the cell morphology. Spherical MCs like Cytodex 1 and 3 generated aggregates with more open structure ( Fig. 2C and D) . The rod shape MCs (DE-53) on the other hand created more compact aggregates ( Fig. 2E and F) . The degree of compactness increased with the decrease in MC size. The increase in the compactness of the cell-MC aggregates had a negative impact on cell yield, presumably due to lack of nutrients for the cells in the center of the aggregates. Cytodex 3 coated with Matrigel has been utilized for hESC expansion by several researchers. Nie et al. (2009) have reported that the hESC line, H1 propagated on Matrigel coated Cytodex 3 has a doubling time of 35 h similar to the 2D plate culture, while Serra et al. (2009) showed that hESC line SCED™461 grew slower with doubling time of 42.6 h. Chen et al. (2011a) have also used coated Cytodex 3 MCs for propagation of HES-3 cells generating an average cell density of 1.1 × 10 6 cells/ml after 7 days of cultivation (HES-3). Furthermore, Nie et al. (2009) showed that cryopreserved cells adhered to Cytodex 3, had better viability and recovery (1.5-1.9 fold increase) when compared to freely suspended colonies.
ECM coated DE-53 cylindrical positively charged MCs were used extensively for propagation of four hESC lines and two hiPSC (Bardy et al., 2013; Chen et al., 2010a Chen et al., , 2010c Chen et al., , 2011a Oh et al., 2009) . Cell densities of 2.8-6.1 × 10 6 cells/ml (14-30 fold expansion) were achieved within 7 days in stirred spinner flask cultures. This MC has high cell attachment rate (over 90% in 2 h). It generated compact cell-MC aggregates efficiently, which can afford single cell seeding and withstand agitated conditions, support growth of hPSC on Matrigel, laminin and without coating in the presence of ROCK inhibitor (Bardy et al., 2013; Chen et al., 2011a; Chen et al., submitted for publication; Oh et al., 2009 ).
Culturing hPSC on MCs
hESCs cultured on MCs can expand to higher cell yields than those on 2D plate culture. Oh et al. (2009) have shown that hESC MC culture yields 2.4-4.3 fold more cells than those on 2D tissue culture plate (maximal cell density of 3.5 × 10 6 cells/ml as compared 0.8-1.5 × 10 6 cells/ml for 2D culture). The higher cell yield from the MC cultures may be attributed to the larger surface area, better oxygen and nutrient transfer (Oh et al., 2009) . Chen et al. (2010c) have also provided more insight on hESC metabolism when comparing MC to 2D cultures. In the presence of mouse embryonic fibroblast-conditioned medium, both 2D and MC cultures had similar doubling times, whereas in serum free medium conditions (StemPro ®hESC SFM or mTeSR®1 SFM), the MC cultures exhibited longer doubling times than those on 2D cultures. hESCs cultured on 2D plates have more divergence in metabolite specific consumption or production rates than those on MC cultures in conditioned and serum free media, which indicate that MC environments are more consistent than the 2D cultures. The difference in cell growth and metabolism between 2D and MC also suggests a need to optimize special growth media for MC expansion.
hESCs and hiPSCs grown on MCs have high ratios of lactate to glucose conversion of 1.8-2.3. These values are higher than the values found in other mammalian cells like Vero and hybridoma cells (1.67-1.77) (Bardy et al., 2013; Chen et al., 2010c) showing the high glycolytic activity of hPSCs. Lactate concentration can be as high as 25 mM in the late stage of the culture (Chen et al., 2010c) . Exposing hESC to lactate as low as 11 mM can result in reduction in cell growth and down-regulation of pluripotent markers. On the other hand, low levels of ammonium are generated in hPSC cultures (0.5-0.8 mM). Up to a level of 1 mM of lactate, no effects on cell growth and pluripotent marker expression were observed. Thus, cell yields can be improved by applying a feeding regime with controlled glucose levels at 1-1.5 g/l. By doing this, lactate accumulation was reduced which resulted in 40% higher cell yields (Chen et al., 2010c) . Further work is needed to examine the metabolism of hPSCs on MCs in a controlled bioreactor. The nutrient metabolism of hPSCs during differentiation has not yet been explored.
Scaling up MC culture for hPSC expansion
Several research groups have demonstrated the feasibility of scaling up hESC expansion in suspension by using the simpler spinner flasks (50-150 ml) without controls for pH and oxygen (Table 4) . Serra et al. (2010) took one step further by combining the MC technology in a bioreactor with automated controls to demonstrate the scalability and standardization of the MC platform for hESC expansion. The group generated 2.17 × 10 6 cells/ml in 11 days with seeding density of 1.5 × 10 5 cells/ml, achieving 15-fold expansion. This limited information on development of efficient large scale hESC MC culture system emphasizes the need for investigating key parameters, such as the seeding and cell transfer procedures, dissolved oxygen, pH control and agitation effects. Conventionally, adherent cells cultured on tissue culture flasks are dissociated into single cells enzymatically prior to seeding onto MCs in order to generate even distribution of cells on MCs. Otherwise, the cell growth and yield might be compromised by uneven cell growth on MCs. Early attempts of culturing hESCs on MCs by Phillips et al. (2008) showed that adapting hESCs to single cell seeding was an important step for the initiation of hESC MC culture. Single cells had better survival when compared to aggregate seeding generated by collagenase treatment. However, Oh et al. (2009) later showed that hPSC clump seeding is also possible resulting in similar cell yields. Single cell seeding as well as clump seeding results in generation of large cell-MC aggregates unlike other adherent cells (e.g. MSC and Vero cells). To have consistent clump seeding of 2D hPSC cells to initiate MC culture, the study used a cell scrapper (EZ passage tool, Life Technologies) which generates uniform cell clumps. Under static conditions, these cell-microcarrier aggregates would expand by attaching to nearby MCs or MC-cell aggregates. Subsequent passaging can be done by simply adding a fraction of MCs coated with cells to new MC (Chen et al., 2010a) . Thus single cell seeding is not necessary for propagating cells on MCs but rather it is important to generate uniform cell-MC aggregates.
Oxygen is one of the parameters that can affect hESC growth and pluripotency, but there are conflicting reports on optimal oxygen level required by hESCs. There are reports suggesting hypoxic conditions are preferred for hESC growth and maintenance of in vitro pluripotency (Covello et al., 2006; Forristal et al., 2010) . However, Serra et al. (2010) showed that dissolved oxygen control at 30% air saturation yielded better cell growth when comparing to 5% air saturation (hypoxic condition) in a controlled bioreactor. They have reported that the different levels of oxygen had no significant effect on the expression level of the pluripotent marker SSEA 4. More research is needed to clarify the controversy.
Another bioprocess parameter that can affect the quality of hESCs is agitation. Lock and Tzanakakis (2009) showed that hESCs propagated on MCs in spinner flask were sensitive to the level of agitation speeds. High agitation speed (80 rpm) resulted in lower cell yield and increased the doubling time when compared to low agitation speed (45 rpm). Another study has reported that different hESC lines propagated on MCs can have different responses to agitation. Under the same agitation condition, HES-3 displayed a decrease in expression of pluripotent markers whereas no significant change was observed in HES-2 (Leung et al., 2010) . No improvement was observed when five different known cell protective polymers (Pluronic-F68, dextran, methylcellulose, polyethylene glycol, and hyaluronic acid) were added into agitated HES-3 MC cultures (Leung et al., 2010) . The nature of MC coatings can also affect hESC sensitivity to agitation. HES-3 propagated in agitated spinner flasks on laminin coated MCs exhibited a significant reduction in expression of pluripotent markers when compared to Matrigel coated ones (Chen et al., 2011a) . Bardy et al. (2013) demonstrated that hiPSC (IMR90) propagated on MCs exhibited improved expressions of pluripotent markers under agitated condition when medium exchanges (80% of total culture volume) was performed twice instead of once per day. This suggests that metabolic conditions in agitated culture can contribute to loss of pluripotency (high lactate levels or low pH generated in the high density cultures). In conclusion, the sensitivity of hPSCs to agitation can be attributed not only to the agitation speed but also to the hPSC lines, culture environment and the coatings on the MCs.
Cell harvesting
Selecting a suitable procedure and conditions for harvesting cells from MCs is important for a successful process. The recombinant proteolytic enzyme TryPLE Express is routinely used to detach hESCs from MCs followed by a 40 μm sieve to remove the MCs (Oh et al., 2009 ). This study showed that harvested cells can be cultured subsequently onto fresh MCs and achieved a similar cell yield to those seeded from cell-MC aggregates that were mechanically dissociated. Other groups like Lock and Tzanakakis (2009) who harvested definitive endoderm cells from MCs used collagenase. Lecina et al. (2010) developed a different harvesting method for cardiomyocytes from MCs which used two enzymes (Collagenase IV and Trypsin) consecutively. Cell harvest methods and conditions depend on the type of cells and MC properties. There have been no systematic studies comparing the methods and conditions for harvesting hPSCs and their differentiated progenies.
Another important point is that these methods are designed for small scale and may not be directly translatable to a scaled-up process. Systems developed for large scale harvesting of other adherent cell lines may be adapted to hPSCs. For example, Lindskog et al. (1987) showed the use of dextranase to remove cells cultured on dextran based MCs. Billig et al. (1983) showed that MC-cell separation can be done by differential centrifugation with Ficoll-Paque™. Rho-kinase inhibitor Y27632, is reported to be effective in preventing dissociated hPSC from undergoing apoptosis (Braam et al., 2010; Chen et al., 2010b; Olson, 2008; Watanabe et al., 2007) . Furthermore, since the harvested cells are the actual product, any residual particles from the MCs should also be removed. Recent development in thermo-sensitive MCs that allow cell detachment via a change in temperature without using any proteolytic enzyme appears quite promising. The thermo-sensitive polymer, poly-N-isopropylacrylamide (pNIPAAm) has been extensively studied. Culturing cells on pNIPAAm coupled MCs (e.g. Cytodex 3, polystyrene, alginate, and polyhydroxyethylmethacrylate beads) has been demonstrated, with efficient cell detachment by decreasing culture temperature from 37°C to below 30°C (Cetinkaya et al., 2011; Hendrick et al., 2001; Kim et al., 2002; Tamura et al., 2012; Yang et al., 2010) .
Differentiation
Differentiated or intermediate progenitor cells of hESCs are required for cell therapy. Therefore, it would be ideal to combine expansion and differentiation of hESCs on MCs within the bioreactor. However, it is a challenge to establish an integrated MC based platform considering that many of the differentiation protocols require several physical manipulations that may include replating, co-culturing, cell selection or passaging. A few groups have had some success in this endeavor. Lock and Tzanakakis (2009) demonstrated the generation of FOXA2 and SOX17 positive definitive endoderm after hESC expansion on MCs. The efficiency was significantly higher (84.2%) on MCs when compared to 63.2% in 2D culture. Cardiomyocyte differentiation is another area where MC can play an important role in fulfilling the need to generate large quantities of cells required for treatment of cardiac infracts. Lecina et al. (2010) screened 5 different MCs and found protamine coated TSKge1 Tresyl-5PW (Tosoh Bioscience) MCs (Ø 10 μm) to be the optimal MCs for cardiomyocyte differentiation. The efficiency was 2 to 3-fold higher in MC culture with 0.28-0.62 cardiomyocyte generated per hESC seeded comparing to 0.13-0.22 via embryoid bodies formation (Lecina et al., 2010; Ting et al., 2012) . However, there are still challenges ahead in developing integrated platforms combining hESC expansion and cardiac differentiation. The bottleneck seems to be at the generation of ideal hESC-MC aggregates prior to differentiation (our unpublished data). Bardy et al. (2013) have also made progress in neural differentiation with MCs. Combining 7 days of hESC expansion with seeding density of 2 × 10 5 cells/ml and 16 day neural differentiation on MCs, more than 300 PSA-NCAM positive neural progenitor cells (NPC) per seeded hESC were generated. One of the major concerns in clinical applications of cells derived from hPSCs is the removal of undifferentiated cell populations, which can generate teratomas after transplantation. To achieve this, several cell separation methods are suggested. For small scale, fluorescence-activated cell sorting is the commonly used method for isolating neural cells (Pruszak et al., 2007) , cardiomyocyte (Dubois et al., 2011; Uosaki et al., 2011; Xu, 2012) and endothelial cells (Levenberg et al., 2002) . A scalable Percoll density centrifugation method has been used in cardiomyocyte separation achieving purity of 70-95% (Cao et al., 2008; Laflamme et al., 2007; Xu, 2012; Xu et al., 2002 ). An immunomagnetric cell sorting platform, which currently is considered as the "gold standard" (Thiel et al., 1998) was described by Schriebl et al. (2010) . Other innovative approaches include the development of a cytotoxic antibody to hPSC (Choo et al., 2008) and generation of recombinant hPSC with specific expression systems that can eliminate non-differentiated cell populations (Anderson et al., 2007; Huber et al., 2007) . Each of these methods has advantages and flaws. Hence, developing an integrated multi-stage cell separation platform is imperative. Schriebl et al. (2012) has demonstrated this concept, where the coupling of immunomagnetic cell sorting with cytotoxic antibody treatment reduced the risk of teratoma formation of purified hESC derived progenitors.
Conclusions and future trends
MCs are a robust and scalable platform for culturing adherent cell lines. It has taken more than four decades from their first invention in 1967 by van Wezel, for the technology to be fully developed and matured. To date, the use of MCs has been limited mainly to vaccine production and research applications. However, with the increase in importance of stem cell bioprocessing, in the last five years, the interest in using the MC platform for this application has re-appeared and a new wave of research towards finding solutions to the difficulties in the expansion of stem cells by using MCs have emerged.
The adaptation of MSCs onto the MC platform has been straightforward since they grow as monolayer cultures similar to other mammalian adherent cell lines. Thus many of the earlier MC studies can be directly adapted. However still more research is needed in several critical issues: the development of reasonably priced chemically defined xeno-free media, finding an efficient large scale cell harvesting method and exploring the interrelations between cell expansion on MCs and the efficiency of differentiation. Moreover, development of biodegradable MCs can be advantageous as MSCs grown on these MCs can be used as the scaffold for in vivo transplantation.
The adaptations of hPSCs onto the MC platform are more challenging than MSCs as these cells grow in multilayer colonies on ECM based matrices. In order to make the MC platform viable, there is a need to optimize properties of MCs (e.g. coating, size and materials). Moreover, due to the need for maintaining pluripotency at the expansion phase and achieving efficient differentiation at the following step, MCs can also be engineered to include other innovative properties like growth factor encapsulation and bio-active matrices, which can facilitate hPSC expansion, differentiation and also preferably in vivo transplantation. Beside issues related to MC structure and its composition there is a need to develop special large scale systems as the hPSC MC platform may not be adapted easily to conventional bioreactors due to shear stress effects. Reasonably priced xeno-free small molecule based media, efficient feeding regimes, and most importantly the development of efficient integrated cell expansion and differentiation processes as well as the downstream harvesting and selection of the desired cells are needed.
In conclusion, the classical MC platform which was developed for biologics production by adherent cells is not optimal for stem cells. There is a need to modify MC technologies and the associated processes which must be tailored to the requirements of the stem cell types of interest, and the clinical applications where they will be used.
